Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)

Background: Semaglutide is a long-acting, subcutaneous (s.c.), glucagon-like peptide-1 analogue that is currently being investigated for obesity management in adults with overweight or obesity in the phase 3 STEP clinical trial program. Varying degrees of weight loss were observed with once-weekly s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kushner, Robert F, Garvey, W Timothy, Hesse, Dan, Koroleva, Anna, Lim, Soo, Lingvay, Ildiko, Mosenzon, Ofri, Wallenstein, Signe O R, Wadden, Thomas A, le Roux, Carel W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Adipose Tissue, Appetite, and Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089676/
http://dx.doi.org/10.1210/jendso/bvab048.046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089676/
http://dx.doi.org/10.1210/jendso/bvab048.046

Ejemplares similares